Welcome Santo Therapeutics to SBC! Gallery

Nezar Clinical Services Joins SBC’s Seed Works Gallery

Survey for mapping project aiming to advance commercialisation of UK life science products Gallery

Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers Gallery

Catalyser applications now open! Gallery

SBC wins Best Performing R&D Facility for second year running at One Nucleus Awards Gallery

LifeArc Ventures is part of investor syndicate for Hillstar Bio who closes $67 million Series A financing round Gallery

Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older Gallery

Job Vacancy: Facilities Officer Gallery

Santo Therapeutics Begins Clinical Trial Targeting NF2-Related Tumours Gallery

MFX Appoints Dr. Katy Newton as Chief Scientific Officer to Drive Innovation for Cell-Based Therapies Gallery

Ternary Therapeutics Arrives at SBC Gallery

Mouthwash to treat side effects of cancer treatment (NG11-2) Phase-Ib clinical study results available Gallery

Monoclonal antibody delivers clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps Gallery

Network established to identify opportunities for regulation to support innovation within advanced therapies Gallery

Samuel Atack Appointed as Operations Director at Stevenage Bioscience Catalyst Gallery

Charles Large, Autifony CEO, talks at the 8th Sachs Neuroscience Innovation Forum in San Francisco Gallery

LifeArc and Neuropeutics Inc join forces to advance a new treatment for MND/ALS Gallery

New AI tool aims to detect early signs of dementia during routine eye tests Gallery

Welcome INDICRO Ltd to Seed Works Shared Office! Gallery